Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AZD6750 Alone and With Rilvegostomig in Advanced Solid Tumors
NCT07115043Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2025
- Primary completion
- Oct 2029
- Countries
- 4
01
Overview
A Phase 2 trial of AZD6750 in melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), renal cell carcinoma (RCC), Merkel cell carcinoma (MCC), sponsored by AstraZeneca. Started Jul 2025; status: recruiting.
02
Drugs
AZD6750
03
Conditions
melanomanon-small cell lung cancer (NSCLC)squamous cell carcinoma (SCC)renal cell carcinoma (RCC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT07115043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115043.